SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description

   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


Speaker
Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC

Speaker Affiliation


Course Director
Gregg Sherman, MD
Chief Medical Officer, NACE
Plantation, FL

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Presenter
Seth Baum, MD, FACC, FACPM,
FAHA, FNLA, FASPC
President, American Society for Preventive Cardiology
Clinical Affiliate
Professor of Biomedical
Science Florida Atlantic University
Founder, Excel Medical Clinical Trials
Boca Raton, FL

Moderator
Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH
Professor of Medicine
Tulane University School of Medicine
Tulane Heart and Vascular Institute
New Orleans, LA



Title
: Making Sense of Evolving Data to Lower CV Risk: Integrating PCSK9 Therapy into Practice
Activity/Course #:
: NCME340
Cost:
: Free
Release/Start Date:
: Nov 15 2017
Expiration Date:
: Nov 14 2018
Topics:
: Cardiovascular
Target Audience:
: Cardiologists and Primary Care Providers
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s)
Hardware/Software Requirements:
Statins are the mainstay of pharmacotherapy for dyslipidemia and reduction of cardiovascular risk. The 2013 American College of Cardiology (ACC) / American Heart Association (AHA) guidelines identified four major statin benefit groups for cardiovascular risk reduction. However, about 10-20% of patients may be intolerant to statin therapy or the appropriate intensities recommended in the guidelines. Statin monotherapy may be insufficient for patients with established cardiovascular disease, diabetes or metabolic syndrome, and asymptomatic high-risk individuals, who require goals beyond total and LDL-C control. The 2016 ACC consensus decision pathway, recently updated in 2017, provides recommendations for the use of non-statin therapies for lowering LDL-C and managing ASCVD risk. Despite the availability of evidence-based guidelines, there exists a wide gap between these recommendations and actual clinical practice.

The program format utilizes an interview style format incorporating a moderator, Dr. Keith Ferdinand, and faculty thought leader, Dr. Seth Baum who will discuss an approach to integrating new data into lipid management strategies for further improving cardiovascular outcomes in the highest risk patients. The program incorporates case based vignettes, didactic presentations, and an interactive discussion with audience participation to deliver information while increasing practitioner skills and confidence in patient evaluation and management. This webcast was recorded live and is being used with the permission of the presenters.

Learning Objective(s):

After completing this program participants should be able to:

  1. Review current recommendations for the use of non-statin therapies in the management of dyslipidemia.
  2. Explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction.
  3. Describe the findings from recent trials of dyslipidemia treatments on cardiovascular outcomes.
  4. Integrate new data into treatment strategies for further improving cardiovascular outcomes in the highest risk patients.

How To Obtain Your CME Certificate

  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists, Inc.
Accreditation Designation Statement
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hours of continuing education (which includes 0.50 pharmacology hour).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed.

Seth Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, Presenter, serves as a scientific advisor and consultant for Sanofi. Dr. Baum also serves as an advisory committee member, consultant and speaker for Amgen and Akcea Therapeutics in addition to an advisory committee member and Consultant for Regeneron.

Keith Ferdinand, MD, FACC, FAHA, FNLA, Moderator serves as a consultant for Amgen, Sanofi, Novartis, Boehringer Ingelheim, and Quantum Genomics.

Gregg Sherman, MD, Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This educational activity is supported by educational funding provided by Amgen.